Thinking about buying stock in Newtek Business Services, Fulcrum Therapeutics, Gamida Cell, PubMatic, or Falcon Capital Acquisition?
NEW YORK, Aug. 11, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NEWT, FULC, GMDA, PUBM, and SHCR.
To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.
- NEWT: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=NEWT&prnumber=081120212
- FULC: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=FULC&prnumber=081120212
- GMDA: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=GMDA&prnumber=081120212
- PUBM: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=PUBM&prnumber=081120212
- SHCR: https://www.investorsobserver.com/lp/pr-stocks-lp-2/?stocksymbol=SHCR&prnumber=081120212
(Note: You may have to copy this link into your browser then press the [ENTER] key.)
InvestorsObserver's PriceWatch Alerts are based on our proprietary scoring methodology. Each stock is evaluated based on short-term technical, long-term technical and fundamental factors. Each of those scores is then combined into an overall score that determines a stock's overall suitability for investment.
View original content to download multimedia:https://www.prnewswire.com/news-releases/thinking-about-buying-stock-in-newtek-business-services-fulcrum-therapeutics-gamida-cell-pubmatic-or-falcon-capital-acquisition-301353253.html
--Piper Sandler Adjusts Fulcrum Therapeutics' Price Target to $46 From $20, Maintains Overweight Rating
MT Newswires 08/17 09:59 ET
--HC Wainwright Adjusts Price Target on Fulcrum Therapeutics to $40 From $20, Maintains Buy Rating
MT Newswires 08/17 09:59 ET
Fulcrum stock leads weekly healthcare gainers; Axsome, Sesen Bio among laggards
SA Breaking News 08/14 14:28 ET
Thinking about buying stock in Biolase, Ziprecruiter, Romeo Power, Venus Concept, or Fulcrum Therapeutics?
PR Newswire 08/13 09:31 ET
--SVB Leerink Adjusts Price Target on Fulcrum Therapeutics to $37 From $23, Maintains Outperform Rating
MT Newswires 08/13 08:53 ET
Fulcrum Therapeutics Prices Common Stock Offering at $19 Per Share
MT Newswires 08/12 04:00 ET
Sharecare to participate in BTIG HIMSS Digital Health Virtual Booth Tour
PR Newswire 08/11 16:56 ET
Oppenheimer Adjusts PubMatic PT to $45 From $50, Maintains Outperform Rating
MT Newswires 08/11 11:53 ET
CohBar, Allied Healthcare Products leads healthcare gainers; Biodesix, Inari Medical among major losers
SA Breaking News 08/11 10:59 ET
--Credit Suisse Raises Fulcrum Therapeutics' PT to $30 from $20 After Positive Interim Data from Phase 1 Trial of FTX-6058, Keeps Outperform Rating
MT Newswires 08/11 10:01 ET